Investors might want to bet on iTeos Therapeutics, Inc. (ITOS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

WATERTOWN, Mass. and GOSSELIES, Belgium, May 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...

Shares of ITOS are moving following the inadvertent release of the second interim analysis of Roche's Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus Tecentriq (atezolizumab) versus Tecentriq ...

iTeos Therapeutics, Inc. has reported its financial results for Q1 2025 and provided an update on its drug development progress, anticipating key interim dataset releases in 2025. Specifically, the ...

Shares of biopharmaceutical company iTeos Therapeutics, Inc. (ITOS) traded 20% higher on Wednesday morning after the company announced its intent to wind down operations and explore asset sales. iTeos ...

iTeos Therapeutics (ITOS) is gearing up to report results from several of its programs in 2024. I believe that investors can benefit here, because there is potential with multiple shots on goal.

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology treatments, announced that its CEO, Michel Detheux, will present at the 43rd ...

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new ...

iTeos Therapeutics (ISIN: US46572C1009), a clinical-stage biotech firm focused on immuno-oncology, advances novel therapies targeting immune checkpoints. North American investors should monitor ...